THORLNC and hepatocellular carcinoma: THOR (testis-associated highly conserved oncogenic long noncoding RNA), a novel LncRNA, was recently identified as an activator of the downstream WNT-catenin signaling pathway, implying that HCC patients with low THOR expression may benefit more from sorafenib treatment [40, 41].